David Belada

University Hospital Hradec Králové — Czech Republic

Medicine · Health Sciences

32h-index7.7kcitations345works2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(280), Chronic Lymphocytic Leukemia Research(157), CAR-T cell therapy research(64), Viral-associated cancers and disorders(52), CNS Lymphoma Diagnosis and Treatment(42)

Publications343 total

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up
Blood Cancer Journal·2026Open Access
Guidelines for the management of adverse events following CD19 CAR-T cell therapy in adult patients with lymphomas and acute lymphoblastic leukaemia – consensus of expert panel from certified centres in Czechia and Slovakia for 2025
Transfuze a hematologie dnes·2025
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
The Lancet·2025· 3 citedOpen Access
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma
Journal of Clinical Oncology·2025Open Access
Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial
Blood·2025· 1 citedOpen Access
Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population
Blood·2025Open Access
Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3
Blood·2025· 1 cited
Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation
Blood·2025Open Access
Improved survival with third-line CAR-T therapy vs alternative treatment in DLBCL: A propensity score–matching analysis
Blood·2025
Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8‑color flow cytometry panel reveals substantial differences among products kinetics and persistence
Blood·2025Open Access
Outcomes of T-cell/histocyte-rich large B-cell lymphoma (THRLBCL): An international LEO/MER and NiHiL collaborative study
Blood·2025Open Access
Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 7
Blood·2025
Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma
Blood·2025
Optimizing risk stratification in patients aged 80+ years with large B-cell lymphoma: Comparison of prognostic indices in three pooled international cohorts
Blood·2025
Validation of novel prognostic models in symptomatic Waldenström's macroglobulinemia based on real-world data
Blood·2025Open Access
Comparable PFS in isolated parenchymal cns vs systemic relapse of DLBCL: Results from a large real-world cohort
Blood·2025Open Access
FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis
Blood·2025Open Access
ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/− lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study
Leukemia·2025Open Access
Long‐Term Real‐World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results
Hematological Oncology·2025Open Access
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma
Blood·2025· 5 citedOpen Access
page 1 of 18Next →

Frequent Co-authors

Marek Trněný(23), Wojciech Jurczak(13), Andrea Janíková(9), Laurie H. Sehn(8), Xiaonan Hong(8), Umberto Vitolo(8), Heidi Móciková(8), Fritz Offner(7), Tina Nielsen(7), Robert Pytlík(7), Vít Procházka(7), Gilles Salles(6), Ian W. Flinn(6), Constantine S. Tam(6), Judith Trotman(6), Jiřı́ Mayer(6), John F. Seymour(5), Armando López‐Guillermo(5), Luc Xerri(5), Pierre Feugier(5)